-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Versigent, Lowers Price Target to $55

Benzinga·07/09/2026 19:27:40
Listen to the news
UBS analyst Joseph Spak maintains Versigent (NYSE:VGNT) with a Buy and lowers the price target from $58 to $55.